Quantumzyme to Participate in BioLogic Summit 2026, Emphasizing AI-Driven Biopharmaceutical Innovation

Quantumzyme Corp., a biotransformation company focused on sustainable pharmaceutical manufacturing, announced its team will attend the second annual BioLogic Summit from January 19-22, 2026, in San Diego. The summit is a premier event focused on applying machine learning and artificial intelligence to design and optimize biotherapeutics. Quantumzyme's participation highlights its strategic commitment to staying engaged in rapidly evolving fields like AI-enabled enzyme engineering and protein design.

The conference offers Quantumzyme's scientific leadership opportunities to participate in technical discussions, share insights with peers, and explore emerging advancements aligned with its internal development efforts. This engagement supports the company's proposed strategic evolution to Quantum Genesis AI Corp., pending FINRA approval. The BioLogic Summit caters specifically to hybrid scientists who integrate experimental and computational methods, reflecting the expertise of the Quantumzyme team.

By attending, Quantumzyme aims to stay informed on the latest developments in generative AI, lab-in-the-loop optimization, and structure-based design approaches. These insights are intended to support the continued advancement of the company's platform and ensure it remains aligned with the most relevant methodologies in the field. The company's focus on sustainable enzyme-based solutions for pharmaceutical manufacturing positions it to contribute meaningfully to discussions about greener manufacturing approaches.

"Innovation doesn't happen in isolation. Being present and actively engaging with the brightest minds in our field is essential to driving our mission forward," stated Naveen Kulkarni, CEO of Quantumzyme Corp. "The BioLogic Summit provides a valuable venue for our team to connect with individuals and organizations who are contributing to the future of AI in biologics. Our goal is to learn from the latest research, better understand emerging challenges, and explore potential collaborations that may support the adoption of greener and more efficient manufacturing approaches across the pharmaceutical industry."

For more information, visit https://www.quantumzymecorp.com and the company's profile at https://www.otcmarkets.com/stock/QTZM. Quantumzyme specializes in green chemistry, applying quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to develop biocatalysts designed to enhance efficiency, reduce waste, and support environmentally responsible production. By integrating computational modeling with laboratory validation, the company aims to deliver scalable, cost-effective biocatalysis solutions that improve industrial sustainability.